Learn how CHI St. Joseph Health is responding to COVID-19. Read More.

Caregiver and Visitor Policy Update. Learn More.

X

2014 Quality Performance Results Table:

 





Measure Number Measure Number    
        ACO Performance Rate Mean performance rate (SSP- ACOs)
ACO-1 Getting Timely Care, Appointments, and Information          84.32 80.13
ACO-2 How Well Your Doctors Communicate          93.78 92.39
ACO-3 Patients’ Rating of Doctor          93.73 91.58
ACO-4 Access to Specialists          82.47 83.97
ACO-5 Health Promotion and Education         54.85 58.29
ACO-6 Shared Decision Making          76.74 74.6
ACO-7 Health Status/Functional Status          71.79 71.1
ACO-8 Risk Standardized, All Condition Readmissions          14.89 15.15
ACO-9 ASC Admissions: COPD or Asthma in Older Adults         1.83 1.08
ACO-10 ASC Admission: HF         1.32 1.19
ACO-11 Percent of Primary Care Providers Who Successfully Attested for the EHR Incentive Program Incentive Payment         61.59 76.71
ACO-12 Medication Reconciliation          96.26 82.61
ACO-13 Falls: Screening for Fall Risk          47.20 45.6
ACO-14 Influenza Immunization         31.63 57.51
ACO-15 Pneumococcal Vaccination         47.45 55.03
ACO-16 Adult Weight Screening and Follow-up         40.88 66.75
ACO-17 Tobacco Use Assessment and Cessation Intervention         67.40 86.79
ACO-18 Depression Screening         4.68 39.27
ACO-19 Colorectal Cancer Screening         10.22 56.14
ACO-20 Mammography Screening         19.71 61.41
ACO-21 Proportion of Adults who had blood pressure screened in past 2 years         25.00 60.24
ACO-22 Hemoglobin A1c Control (HbA1c) (          67.49 N/A
ACO-23 Low Density Lipoprotein (LDL) (         N/A N/A
ACO-24 Blood Pressure (BP)           62.32 N/A
ACO-25 Tobacco Non-Use          73.40 N/A
ACO-26 Aspirin Use          72.16 N/A
ACO-27 Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent)         24.57 20.35
ACO-28 Percent of beneficiaries with hypertension whose BP         61.80 68.02
ACO-29 Percent of beneficiaries with IVD with complete lipid profile and LDL control         N/A N/A
ACO-30 Percent of beneficiaries who use Aspirin or other antithrombotic         79.26 80.79
ACO-31 Beta-Blocker Therapy for LVSD         88.89 82.71
ACO-32 Drug Therapy for Lowering LDL-Cholesterol         N/A N/A
ACO-33 (ACE) Inhibitor or (ARB) Therapy for Patients with CAD and Diabetes and/or (LVSD)         67.90 N/A